So far, none of therapeutic interventions evaluated in PSP have been proven to have sufficient effectiveness, despite over 30 drugs having been tested; the molecules’ targets were designed based on discussions of pathophysiology (mostly tau aggregation and accumulation slow-down or microglia activation inhibition) [41]. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.